Abstract: A method and/or system for analyzing data using population clustering through density based merging.

Abstract: A method of electronic portal imaging (EPID) for radiation dosimetric measurement and quality assurance (QA) in radiation therapy is provided that includes imaging a calibration photon beam and a treatment beam using an EPID imager disposed between a plastic water build-up phantom and a plastic water back-scatter phantom that is thicker than the plastic water build-up phantom, correcting the EPID images using an off-axis correction map that takes into account a horn-shape of a photon fluence profile, deconvolving the corrected EPID images using a Monte Carlo simulated EPID response kernel, the deconvolved corrected EPID images provide a primary photon fluence map, reconstructing a relative dose map using the primary photon fluence map convolving with a Monte Carlo simulated pencil-beam dose distribution kernel, and generating an absolute dose map using cross calibration to a 10×10 cm2 square field that is compared with a planned dose distribution for QA analysis.

Abstract: Novel human interleukin-2 (IL-2) muteins or variants thereof, and nucleic acid molecules and variants thereof are provided. Methods for producing these muteins as well as methods for stimulating the immune system of an animal are also disclosed. In addition, the invention provides recombinant expression vectors comprising the nucleic acid molecules of this invention and host cells into which expression vectors have been introduced. Pharmaceutical compositions are included comprising a therapeutically effective amount of a human IL-2 mutein of the invention and a pharmaceutically acceptable carrier. The IL-2 muteins can be used in pharmaceutical compositions for use in treatment of cancer and in stimulating the immune response.

Abstract: A multiplying analog to digital converter including an analog to digital converter (ADC) having a sample input and a feedback input and an ADC output configured with a feedback path configured to couple the ADC output to a digital to analog converter. A feedback attenuator is disposed in the feedback path, the feedback attenuator being configured to attenuate a feedback signal coupled to the feedback input, the feedback attenuator being configured to provide analog multiplication observed at the ADC output. A barrel shifter is configured to provide digital multiplication of the ADC output. The feedback attenuator may be configured as a divider network. The feedback attenuator may be configured to provide attenuation using only passive components. The feedback attenuator may be configured as a capacitive divider network. The feedback attenuator may be configured to provide attenuation ranging between 1 and 0.5.

Abstract: The present invention provides a method of reducing a subject's hepatic and plasma triglyceride levels comprising administering to a subject in need thereof a pharmaceutical composition comprising a pharmaceutical carrier and a compound that increases PHLPP2 in liver cells in an amount effective to reduce the subject's hepatic and plasma triglyceride levels. The present invention also provides a method of reducing a subject's hepatic and plasma triglyceride levels comprising administering to a subject in need thereof a pharmaceutical composition comprising a pharmaceutical carrier and a compound that increases free Raptor in liver cells in an amount effective to reduce the subject's hepatic and plasma triglyceride levels.

Abstract: BN nanosheets are prepared by a method comprising heating to a temperature of at least 500° C., a mixture comprising: (1) an alkali borohydride, and (2) an ammonium salt. NaN3 may be included to increase the yield. No catalyst is required, and the product produced contains less than 0.1 atomic percent metal impurities.

Abstract: The present invention relates to disubstituted triazoles, their synthesis, and their use as anti-cancer compounds. In particular, compounds of Formula (I) are provided.

Abstract: It has been discovered that the neuropeptides secretin, oxytocin and vasopressin can be administered as therapeutic agents alone or in various combinations to treat dry eye and dry mouth. Based on these discoveries and the results described, certain claims are directed to pharmaceutical compositions formulated for topical oral or ophthalmic use comprising therapeutically or prophylactically effective amounts of the neuropeptides secretin, oxytocin and secretin alone, or in various combinations.

Abstract: A device for manipulating tissue at a vessel includes an elongated member having a proximal end and a distal end, a guide member at the distal end of the elongated member, the guide member having a blunt distal tip for engagement against an interior wall of the vessel, and a tissue cutting device at the distal end of the elongated member, wherein the tissue cutting device has a sharp tip that is proximal to the blunt distal tip of the guide member.

Abstract: The invention includes compositions, methods and kits for the in vivo identification of an enzyme that binds to a substrate. The invention comprises, in part, a photoreactive moiety to aid in identification of such an enzyme.

Abstract: Myeloid function is enhanced by transplantation or infusion of allogeneic myeloid progenitor cells, including CMP, GMP, MEP and MKP cell subsets. Myeloid progenitors ameliorate sequelae of anemia and thrombocytopenia, and can prevent or treat gastrointestinal mucositis associated with chemotherapy, radiotherapy, and the like. The transplantation or infusion may be performed in the absence of HLA typing, and the cells may be mismatched at one or more Class I HLA loci. The transplantation may provide for treatment of ongoing disease, or prevention of disease in high risk patients.

Abstract: High affinity PD-1 mimic polypeptides are provided, which (i) comprise at least one amino acid change relative to a wild-type PD-1 protein; and (ii) have an increased affinity for PD-L1 relative to the wild-type protein. Compositions and methods are provided for modulating the activity of immune cells in a mammal by administering a therapeutic dose of a pharmaceutical composition comprising a high affinity PD-1 mimic polypeptide, which blocks the physiological binding interaction between PD-1 and its ligand PD-L1 and/or PD-L2.

Abstract: Cancer treatment is provided, by irradiating an individual with a localized, high single dose or short course of doses at a primary tumor site; collecting T cells from the individual after a period of time sufficient activation of an anti-tumor response; treating the individual with an effective dose of dose of chemotherapy; and reintroducing the T cell population back to the individual.

Abstract: Methods and compositions are provided for treating pain in an individual. Aspects of the methods include administering to the individual an agent that promotes ALDH activity. These methods find many uses, for example in treating and preventing nociceptive pain, inflammatory pain, and neuropathic pain.

Abstract: A method for producing nanoparticles on a substrate using a metal precursor in an ionic liquid and microwave heating is described. The composite compositions are useful as catalysts for chemical reactions, fuel cell, supercapacitor and battery components, and the like.

Abstract: A method for reducing pulmonary hypertension in a mammal that employs FK506 is provided. In certain embodiments, the method comprises administering FK506 to a mammal having pulmonary arterial hypertension associated with defective MBPR2 signaling at a dosage sufficient to reduce blood pressure in the pulmonary artery of the mammal.

Abstract: The present invention includes a method of treating or preventing a disease or disorder such as a mycobacterial infection, a Gram-positive bacterium infection, a yeast infection, an inflammatory condition, an auto-immune disorder and/or a proliferative disorder in a subject in need thereof. The method comprises administering to the subject a therapeutically effective amount of at least one compound of the invention, which includes clofazimine derivatives.

Abstract: A potent complement regulator is disclosed. The complement regulator comprises a complement regulatory region connected by a flexible linker to a multifunctional binding region that enables binding to C3b activation/inactivation products and/or oxidation end products, as well as to polyanionic surface markers on host cells. An embodiment of the invention utilizes factor H SCRs 1-4 as the complement regulatory region and factor H SCRs 19 and 20 as the multifunctional binding region, linked together by a poly-Gly linker at least 12 residues in length. Pharmaceutical compositions comprising the complement regulator and methods of using the complement regulator are also disclosed.

Abstract: The present invention provides triterpenoids produced from natural compounds such as oleanolic acid, ursolic acid, betulinic acid, and hederagenin.

Abstract: Provided are compositions and methods that permit a hybrid nucleic acid-peptide molecule to enter a cell and when specifically activated within the cell, the molecule anneals to endogenous cellular RNA and permits the isolation of the RNA.